1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-36.98%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-26.05%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-129.84%
Negative EBIT growth while 6617.T is at 3.21%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-151.38%
Negative operating income growth while 6617.T is at 4.04%. Joel Greenblatt would press for urgent turnaround measures.
-173.20%
Negative net income growth while 6617.T stands at 87.90%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-173.27%
Negative EPS growth while 6617.T is at 87.89%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-173.27%
Negative diluted EPS growth while 6617.T is at 87.89%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.63%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-13.63%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
112.34%
10Y revenue/share CAGR above 1.5x 6617.T's 4.81%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
41.54%
5Y revenue/share CAGR above 1.5x 6617.T's 7.83%. David Dodd would look for consistent product or market expansions fueling outperformance.
10.69%
3Y revenue/share CAGR similar to 6617.T's 10.42%. Walter Schloss would assume both companies experience comparable short-term cycles.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.41%
Negative 10Y net income/share CAGR while 6617.T is at 44.76%. Joel Greenblatt sees a major red flag in long-term profit erosion.
48.41%
Below 50% of 6617.T's 649.34%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-9.44%
Negative 3Y CAGR while 6617.T is 1838.90%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
119.65%
10Y equity/share CAGR above 1.5x 6617.T's 15.93%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
36.70%
5Y equity/share CAGR above 1.5x 6617.T's 13.53%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
25.80%
3Y equity/share CAGR above 1.5x 6617.T's 14.79%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.79%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
13.43%
Inventory growth well above 6617.T's 12.05%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-7.95%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
3.07%
BV/share growth above 1.5x 6617.T's 1.22%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-4.40%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-18.67%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
19.64%
SG&A growth well above 6617.T's 13.70%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.